Tag: american society of hematology (ASH)

rogers_adamts13_650x450
March 2, 2022/Blood Cancers

Updated Guidelines for Immune Thrombocytopenic Purpura Focus on Treating Patients Without Bleeding

Management options expand in both inpatient and outpatient settings

Acute lymphoblastic leukemia ALL-L2 blood smear under light microscopy
February 1, 2022/Blood Cancers

New Drug Combination Can Extend the Lives of Older Patients with Ph+ Acute Lymphoblastic Leukemia

Novel regimen may help overcome the shortcomings of traditional chemotherapy in geriatric population

Human liver tissue with Amyloidosis under a microscope.
January 25, 2022/Blood Cancers

Addition of CAEL-101 to Anti-Plasma Cell Dyscrasia Therapy May Have Long-Term Benefits in Patients with AL Amyloidosis

Follow-up study confirms safety and tolerability of new treatment protocol

22-CNR-2623310 CQD ASH 2021 650×450
January 19, 2022/Blood Cancers

Top Abstracts to Watch from ASH 2021

Experts highlight the newest, most compelling hematology abstracts

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Chimeric antigen receptor (CAR) therapy,
December 14, 2021/Blood Cancers

Biomarkers Predict Outcomes of CAR T-Cell Therapy in Patients with Diffuse Large B-Cell Lymphoma

Treatment may be a lifesaving option for patients with relapsed or refractory disease

nci-vol-11852_650x450
December 13, 2021/Research

Modified Drug Regimen May Reduce Risks in Allogeneic Hematopoietic Cell Transplant Patients

Study suggests new approach is safer than standard treatment and may help prevent graft-versus-host disease

trials-data-sharing_650x450
January 28, 2016/Research

Common Eligibility Criteria in Randomized Clinical Trials of Hematologic Malignancies May Be Too Stringent

Study suggests re-examining eligibility criteria for randomized controlled trials of hematologic malignancies.

ASHbanner_690x380
January 18, 2016/Research

The 10 Most Compelling Abstracts from ASH 2015

Takeaways from Cleveland Clinic’s hematology/medical oncology experts

ASHbanner_690x380
December 7, 2015/Blood Cancers

New Model Improves Prognostication for MDS and CMML Patients

Molecular data enhance traditional scoring systems

ASHbanner_690x380
December 7, 2015/Blood Cancers

Rational Treatment Modifications to Extend Responses to 5-Azacytidine and Decitabine

Research improving myelodysplastic syndromes treatment

BackPage 1 of 3Next
Advertisement
Ad